Straits Times Index
3,388.52 +7.68 (+0.23%) S&P 500
4,164.00 +52.92 (+1.29%) Dow
34,156.69 +265.67 (+0.78%) Nasdaq
12,113.79 +226.34 (+1.90%) BTC-USD
23,183.90 +202.75 (+0.88%) CMC Crypto 200
535.03 +9.08 (+1.73%)
Novartis AG (NVSEF)
| Previous close | 82.73 |
| Open | 84.61 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 84.61 - 84.61 |
| 52-week range | 72.98 - 93.58 |
| Volume | |
| Avg. volume | 72,632 |
| Market cap | 185.193B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 27.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.49 (4.22%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- Zacks
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
- Motley Fool
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2022.
- Reuters
Novartis says operating profit to grow again ahead of Sandoz spin-off
Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.
